Christopher Morabito
CIK 1859284 · Chief Medical Officer · last filed 2026-01-23
Christopher Morabito is a Chief Medical Officer who has filed 12 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing, for ATXS, was dated Jan 23, 2026. Across all open-market trades the lifetime net is −$237.2K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $4.3K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$4.3K
2
12
-$237.2K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Astria Therapeutics, Inc. (ATXS) Delisted | Chief Medical Officer | 0 | $12.58 | $0 | -$247.3K | 7 | 2026-01-23 |
| FULC | Chief Medical Officer | 1,100 | $3.87 | $4.3K | $10.1K | 3 | 2022-01-21 |
Recent Filings
12 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-23 | Astria Therapeutics, Inc. (ATXS) Delisted | Disp (D) | — | $0 | EDGAR |
| 2025-03-25 | Astria Therapeutics, Inc. (ATXS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-04-03 | Astria Therapeutics, Inc. (ATXS) Delisted | Mixed | — | -$97.2K | EDGAR |
| 2024-04-01 | Astria Therapeutics, Inc. (ATXS) Delisted | Notice (144) | −10,000 | -$135.9K | EDGAR |
| 2024-02-12 | Astria Therapeutics, Inc. (ATXS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-01-30 | Astria Therapeutics, Inc. (ATXS) Delisted | Mixed | — | -$72.7K | EDGAR |
| 2024-01-29 | Astria Therapeutics, Inc. (ATXS) Delisted | Notice (144) | −9,200 | -$102.6K | EDGAR |
| 2023-06-06 | Astria Therapeutics, Inc. (ATXS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-08-02 | Astria Therapeutics, Inc. (ATXS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-01-21 | FULC | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.